Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) Target Price at $7.75

Bausch Health Companies Inc. (NYSE:BHC) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.75.

A number of brokerages have recently weighed in on BHC. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada boosted their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Bausch Health Companies Trading Up 0.7 %

NYSE BHC opened at $7.53 on Friday. The stock has a fifty day simple moving average of $8.30 and a 200-day simple moving average of $7.31. The stock has a market cap of $2.72 billion, a PE ratio of -15.69 and a beta of 0.69. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the business posted $1.03 EPS. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. Research analysts predict that Bausch Health Companies will post 3.74 EPS for the current year.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Asset Management Inc raised its holdings in Bausch Health Companies by 0.3% during the third quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock worth $3,060,000 after purchasing an additional 1,082 shares in the last quarter. Bfsg LLC grew its position in shares of Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after buying an additional 3,643 shares during the last quarter. Northwest & Ethical Investments L.P. raised its stake in Bausch Health Companies by 13.0% during the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock worth $264,000 after acquiring an additional 3,734 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Bausch Health Companies by 6.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock valued at $423,000 after acquiring an additional 3,923 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Bausch Health Companies by 2.0% in the second quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock valued at $1,719,000 after acquiring an additional 4,944 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.